Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2022, 47(4): 233
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2022 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2022.47.4.3381589
 
 
Ciltacabtagene autoleucel. CAR-T therapy targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma
Lee, S., Cowan, A.J.
 
 
Multiple myeloma (MM) is a plasma cell neoplasm that affects an estimated 7.1/100,000 people per year in the United States. Disease morbidity results from end-organ damage with renal dysfunction, hypercalcemia, anemia and osteolytic bone lesions. The median age at diagnosis is 69 years and, per the SEER database, the 5-year relative survival is 55.6%. Although outcomes have improved for MM with effective upfront treatment, including use of proteasome inhibitors, immunomodulatory agents and autologous stem cell transplantation, the disease is considered largely incurable and nearly all patients will relapse. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed MM targeting B-cell maturation antigen (BCMA), a highly expressed antigen on the surface of malignant plasma cells. In the phase Ib/II CARTITUDE-1 trial, cilta-cel was administered to 97 patients at a dose of 0.75 x 10(6) CAR+ cells/kg with high overall response rates (97%), and a significant proportion of stringent complete responses in 67% of patients. The median progression-free survival was not reached. Currently, there are ongoing studies of cilta-cel in relapsed MM, including a phase II study (CARTITUDE-2), a phase III study in relapsed MM, and a study of cilta-cel in newly diagnosed MM.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences